Delgocitinib (2) – Anzupgo®
Chronic hand eczema, aged ≥ 12 to < 18 years
Characteristics
| Start date | 15.11.2026 |
|---|---|
| Resolution | 05.05.2027 – active procedure |
| INN | Delgocitinib |
| Brand name | Anzupgo® |
| Pharm. company | LEO Pharma GmbH |
| G-BA Procedure ID | D-1397 |
| Therapeutic area | Skin diseases |
| Reason for procedure | New therapeutic indication |
Associated procedures
| Delgocitinib (2) | Anzupgo® | LEO Pharma GmbH | Chronic hand eczema, aged ≥ 12 to < 18 years | n.d. | active procedure | |
| Delgocitinib (1) | Anzupgo® | LEO Pharma GmbH | Moderate to severe chronic hand eczema | 160,000–200,000 | 100% additional benefit not proven |
<< List of all resolutions